(Total Views: 373)
Posted On: 05/02/2017 1:54:01 AM
Post# of 72446
Clinical trial data is due soon for the Brilacidin formulations for oral mucositis and for ulcerative proctitis. Psoriasis drug Prurisol data should be forthcoming in the 3rd quarter, with the additional clinical trial sites now recruiting.
I'm not sure whether we're at the stage of the rocket being wheeled out onto the launch pad, or whether it's on the launch pad and being fueled, but you get the idea of what could happen soon.
Having seen the disaster that befell NTRP today because they 1) had a faulty design for their clinical trial -- didn't allow a long enough time frame to get results that could be compared to other drugs, and 2) had so-so results, and 3) utterly botched the data analysis and its presentation --- I am very glad that we have 3 formulations of Brilacidin for totally different conditions, and Prurisol, and Kevetrin, all in clinical trials which have succeeded thus far. Even if one drug were to fail, we have fall-back drug trials. NTRP does not have that, nor do most small biotechs.
I'm not sure whether we're at the stage of the rocket being wheeled out onto the launch pad, or whether it's on the launch pad and being fueled, but you get the idea of what could happen soon.
Having seen the disaster that befell NTRP today because they 1) had a faulty design for their clinical trial -- didn't allow a long enough time frame to get results that could be compared to other drugs, and 2) had so-so results, and 3) utterly botched the data analysis and its presentation --- I am very glad that we have 3 formulations of Brilacidin for totally different conditions, and Prurisol, and Kevetrin, all in clinical trials which have succeeded thus far. Even if one drug were to fail, we have fall-back drug trials. NTRP does not have that, nor do most small biotechs.
(2)
(0)
